American Heart Journal
Volume 153, Issue 5 , Pages 837-842 , May 2007

Absence of bilateral vision loss from amiodarone: A randomized trial

This study was presented in part at the annual meeting of the North American Neuro-Ophthalmological Society on February 27, 2006, in Tuscon, AZ.

  • Joel S. Mindel, MD, PhD

      Affiliations

    • Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY
    • Department of Pharmacology and Biochemistry, Mount Sinai School of Medicine, New York, NY
    • Corresponding Author InformationReprint requests: Joel S. Mindel, MD, PhD, Department of Ophthalmology, Box 1183, The Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029.
    • ,
  • Jill Anderson, RN

      Affiliations

    • Seattle Institute for Cardiac Research, University of Washington, Seattle, WA
    • Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, NC
    • ,
  • George Johnson, BSEE

      Affiliations

    • Seattle Institute for Cardiac Research, University of Washington, Seattle, WA
    • ,
  • Anne Hellkamp, MS

      Affiliations

    • Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, NC
    • ,
  • Jeanne E. Poole, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC
    • ,
  • Daniel B. Mark, MD, MPH

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC
    • ,
  • Kerry L. Lee, PhD

      Affiliations

    • Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, NC
    • ,
  • Gust H. Bardy, MD

      Affiliations

    • Seattle Institute for Cardiac Research, University of Washington, Seattle, WA
    • ,
  • for the SCD-HeFT Investigators

Received 26 January 2007 ,Accepted 9 February 2007.

References 

  1. Hattenbauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103–107
  2. Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc. 1987;62:702–717
  3. Johnson LN, Krohel GB, Thomas ER. The clinical spectrum of amiodarone induced optic neuropathy. J Natl Med Assoc. 2004;96:1477–1491
  4. Stelfox HT, Ahmed SB, Fiskio J, et al. Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice. Clin Pharmacol Ther. 2004;75:110–122
  5. Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic anterior ischemic optic neuropathy: a case-control study of potential risk factors. Arch Ophthalmol. 1997;115:1403–1407
  6. Hayreh SS, Joos KM, Podhajsky PA, et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118:766–780
  7. Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol. 1982;66:676–679
  8. Ghosh M, McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol. 1984;19:178–186
  9. Bardy GH, Lee KL, Mark DP, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  10. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care. 1998;21:518–524
  11. Fields LE, Birt VL, Cutler JA, et al. The burden of adult hypertension in the United States. A rising tide. Hypertension. 2004;44:398–404
  12. Grant SW, Schuman J. Chapter 1. Introductory outline of toxic effects on the eyes and vision. In: Toxicology of the eye. 4th ed.. Springfield (IL): Charles C. Thomas Publisher; 1993;p. 30
  13. Nagra PK, Foroozan R, Savino PJ, et al. Amiodarone-induced optic neuropathy. Br J Ophthalmol. 2003;87:420–422
  14. Sreih AG, Schoenfeld MH, Marieb MA. Optic neuropathy following amiodarone therapy. PACE. 1999;22:1108–1110
  15. Palimar P, Cota N. Bilateral anterior ischaemic optic neuropathy following amiodarone. Eye. 1998;12:894–895
  16. Seemongal-Dass RR, Spencer SR. Bilateral optic neuropathy linked with amiodarone. Eye. 1998;12:474–477
  17. GittingerJr JW, Asdourian GK. Papillopathy caused by amiodarone. Arch Ophthalmol. 1987;105:349–351
  18. Eryilmaz T, Atilla H, Batioglu F, et al. Amiodarone-related optic neuropathy. Jpn J Ophthalmol. 2000;44:565–568
  19. Nazarian SM, Jay WM. Bilateral optic neuropathy associated with amiodarone therapy. J Clin Neuroophthalmol. 1988;8:25–28
  20. Castella DD, Teitelbaum BA, Tresley DJ. Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy. Optometry. 2002;73:113–121
  21. Speicher MA, Goldman MH, Chrousos GA. Amiodarone optic neuropathy without disc edema. J Neuroophthalmol. 2000;20:171–172
  22. Purvin V, Kawasaki A, Borraut FX. Optic neuropathy in patients using amiodarone. Arch Ophthalmol. 2006;124:696–701
  23. Totah RA, Rettie AE. Cytochrome P450 2C8: Substrates inhibitors, pharmacogenetics and relevance. Clin Pharmacolb Ther. 2005;77:341–352
  24. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs. 2004;4:281–297
  25. Lesko LJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet. 1989;17:130–140

 This study was supported by grants from the National Heart, Lung, and Blood Institute and the National Institutes of Health (U01 HL55766, U01 HL55496 and U01 HL55788-05); Medtronic, Minneapolis, MN; Wyeth-Ayerst Pharmaceuticals; and the Janet C Weis 1997 Charitable Lead Unitrust.

 Drs Bardy and Lee received research funding from Wyeth-Ayerst Pharmaceuticals.

PII: S0002-8703(07)00143-3

doi: 10.1016/j.ahj.2007.02.010

American Heart Journal
Volume 153, Issue 5 , Pages 837-842 , May 2007

Article Tools